The scientific organizers welcome the submission of original Neuroblastoma research for presentation at ANR2018 in San Francisco. The biennial Advances in Neuroblastoma Research Congress is the leading international forum for sharing the most recent advances in basic, translational and clinical Neuroblastoma research.
ANR welcomes the submission of abstracts on the topics listed below. To facilitate the review process, three abstract categories have been developed for ANR2018.
Other critical pathways
Genomic instabiility/DNA repair
Tumor initiaton and cancer stem cells
Novel targeted therapy (preclinical)
Therapy response and resistance
Novel targeted therapy in development (clinical)
Clinical trial biomarker development and design
Imaging and diagnostics
Nursing related topics
Trials in countries with limited resources
Survivorship and late effects
The abstract submission deadline is January 8, 2018 at 11:59pm PST
Submissions must be data-driven or assessment/treatment model descriptions.
Please note that all abstracts must be sponsored by a Full Member of ANRA with fully paid dues. Any Full Member may sponsor up to 5 abstracts. A sponsor may be a co-author or only a sponsor. The ANRA membership number and sponsor name must be entered in your contact information before submission of your abstract. Associate members will require a Full Member to sponsor an abstract. If you wish to join as a Full Member now, please click here.
The abstract word limit is 350 words with English characters; if you use accents, umlauts, etc., the abstract will count them as additional words (please use the Special Characters keyboard).
The abstract title limit is 20 words with English characters; if you use accents, umlauts, etc., the abstract will count them as additional words
The Review Panel will review and determine which abstracts receive awards, as well as the most appropriate presentation format (oral or poster) for each accepted abstract.
Awards will be given to the top scoring abstracts submitted in each of the main categories, please click here for further details.